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ABSTRACT 
 
X-linked agammaglobulinemia (XLA) is a rare genetic disorder caused by 
mutations in the Bruton’s tyrosine kinase (BTK) gene.  These mutations cause defects in 
early B cell development.  A patient with no circulating B cells and low serum 
immunoglobulin isotypes was studied as were his mother and sister.  Flow cytometry 
showed the patient lacked BTK protein expression in his monocytes while the mother 
and sister had 62% and 40% of the monocytes showing BTK protein expressions, 
respectively.  Results from genetic studies revealed that the patient had a novel base 
substitution in the first nucleotide of intron 9 in the BTK gene, and the mutation was 
IVS9+1G>C.  This mutation resulted in exon 9 skipping, and a loss of 21 amino acids.  
This defect rendered the patient susceptible to recurrent pyogenic infections, otitis 
media, bronchopneumonia, asthma, and failure to thrive.  Genetic study revealed that 
both mother and sister have heterozygous alleles at the similar mutational point as in the 
patient, confirming that both were carriers.  This study supports the necessity of 
combining flow cytometry and genetic study in the diagnosis of XLA and the 
information obtained would be useful for subsequent genetic counseling, carrier 
detection and prenatal diagnosis.   
 
 
Key words: Bruton’s tyrosine kinase, BTK gene, splice site mutation, X-linked 
agammaglobulinemia, exon skipping, BTK protein 
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ABSTRAK 
 
‘X-linked agammaglobulinemia’ (XLA) adalah penyakit genetik yang jarang 
berlaku, disebabkan oleh mutasi dalam gen Bruton’s tyrosine kinase (BTK).  Mutasi 
tersebut mengakibatkan kecacatan dalam perkembangan awal sel B.  Seorang pesakit 
yang tidak mempunyai sel B dan kekurangan semua ‘isotype’ serum immunoglobulin 
diuji bersama dengan ibu dan kakaknya.  Keputusan ‘flow cytometry’ menunjukkan 
pesakit tersebut tidak mempunyai ekspresi protin BTK dalam monositnya manakala ibu 
dan kakaknya mempunyai 62% dan 40% monosit menunjukkan ekspresi BTK masing-
masing.  Keputusan ujian genetik menunjukkan bahawa pesakit tersebut mempunyai 
gantian bes yang baru pada nukleotida pertama ‘intron’ 9 dalam BTK gen, dan mutasi 
tersebut adalah IVS9+1G>C.  Mutasi tersebut mengakibatkan loncatan ‘exon’ 9, dan 
kehilangan 21 asid amino.  Kecacatan tersebut mengakibatkan pesakit tersebut 
cenderung kepada jangkitan bakteria berulangan, keradangan telinga, radang paru-paru, 
asma, dan kegagalan membesar.  Ujian genetik menunujuk bahawa ibu dan kakak 
adalah ‘heterozygous alelle’ dalam titik mutasi yang sama dengan pesakit tersebut, 
kedua-dua mereka dikelaskan sebagai pembawa kepada penyakit tersebut.  Kajian ini 
menyokong kepentingan untuk menggabungjalinkan keputusan ‘flow cytometry’ dan 
ujian genetik dalam diagnosi penyakit XLA.  Maklumat yang didapati dari kedua-dua 
kaedah ini dapat diguna untuk kaunseling genetik, pengesahan pembawa penyakit dan 
diagnosi pra-natal.    
 
Kata-kata kunci: Bruton’s tyrosine kinase, gen BTK, mutasi mencapah, ‘X-linked 
agammaglobulinemia’, locatan ‘exon’, protin BTK 
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1.0 INTRODUCTION  
 
Primary immunodeficiencies (PIDs) are disorders in which particular component 
of the body's immune system is absent or does not function properly.  PIDs are caused 
by mutation in a particular gene.  The molecular defect may result in the defects 
involving humoral, cellular, or innate immunity.  The main characteristic of PID 
patients is an enhanced susceptibility to infections (Notarangelo, 2010).   
B cell defects account for around 50% of PIDs (Eley, 2008).  Children suffering 
PIDs due to B cell defects tend to present at around 4 to 6 months of age when mother’s 
passively transferred immunity starts to decline (Tóth et al., 2009).  Patients with B cell 
defects may have low amount of antibody-producing B cells or non-functional B cells 
leaving them susceptible to infections.  They frequently present with recurrent ear, nose, 
throat and airway infections caused mainly by extracellular encapsulated bacteria such 
as Streptococcus pneumonia, Haemophilus influenza or Pseudomonas species (Basile et 
al., 2008).  
X-linked agammaglobulinemia (XLA) is a classic example of B cell defects.  
XLA was reported with an estimated prevalence of 1 in 200,000 live births, in a BTK 
database (Valiaho, Smith, & Vihinen, 2006).  XLA is caused by mutations in the 
Bruton’s tyrosine kinase (BTK) gene (Vetrie et al., 1993).  Generally, a clinical 
diagnosis of XLA is made if the patient has very low or no circulating B cells, low 
serum immunoglobulin levels and a history of recurrent bacterial infections at early age 
with or without a positive family history.  However, only 85% of the patients who 
comply with these clinical criteria have BTK gene mutations, the remaining 15% 
patients are caused by other genes (Conley et al., 2005).  Hence, a definitive laboratory 
testing is needed to confirm the diagnosis.  Characterization of the BTK gene mutation 
in the patient enables the identification of other family members who carry the similar 
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mutation.  Hence, affected male siblings of the patient who confirmed with BTK gene 
mutations can be tested before the onset of any symptoms and given early treatment.  
Early treatment could avoid unnecessary disease complication in those patient’s male 
siblings.  For example, delay in the treatment of some infections and conditions can lead 
to complication such as bronchiectasis.  This complication can affect the patient’s 
quality of life (QOL) and expectancy.       
Besides that, information on XLA incidence in Malaysia is very scarce.  To date, 
there are very few reports describing the clinical features and laboratory findings of 
Malaysian XLA patients (Noh et al., 2013; Okoh et al, 2002).  This reflects the needs 
for more confirmatory laboratory tests to be set up to confirm the diagnosis.  A 
definitive diagnosis will undoubtedly enable the clinicians to treat the patients 
appropriately.  As a result, the patients will be able to live a more normal life and avoid 
excessive hospitalization. 
 
1.1 Objectives 
 
The objectives of this study were: 
 To investigate X-linked agammaglobulinemia and the carrier status in a 
suspected patient and his family members. 
 To investigate the monocyte Bruton’s tyrosine kinase protein expression by flow 
cytometry. 
 To investigate the genetic mutations involved in cDNA and genomic DNA level 
in the patient and the carriers. 
 To set up a reliable XLA diagnosis system using small sample volume of whole 
blood for routine clinical usage in the Institute for Medical Research (IMR), 
Malaysia.   
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1.2 Thesis organization 
 
This thesis consists of six chapters, which are introduction, literature review, 
methodology, results, discussion and lastly the summary.  Chapter one contains the 
general introduction to the research concerned and the objectives of the study.  Secondly, 
in the literature review chapter, a general introduction of Primary Immunodeficiency 
diseases, B cell development and followed by the description of X-linked 
agammaglobulinemia, the roles of Bruton’s tyrosine kinase protein and so on, are 
discussed.  Methodology chapter describes and explains the research methodology used 
in this study.  In this study, a Malay boy who was clinically diagnosed as X-linked 
agammaglobulinemia was recruited.  The clinical, immunological and genetic 
investigations of the patient are described in the result part of this thesis.  Besides that, 
the patient’s mother and sister were recruited in this study to determine the carrier status 
in the family.  Discussion chapter contains the interpretation of the results and also 
research finding comparison between this study and previous studies in the literature.  
Last but not least, all findings are summarized in the summary part.      
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2.0 LITERATURE REVIEW 
 
2.1      Primary Immunodeficiency diseases  
 
Primary immunodeficiencies (PIDs) are inherited disorders that affect the 
development, function, or both of the body’s immune system (Notarangelo, 2010).  In 
most cases of PIDs, the disorders are caused by single gene mutation; however, some 
PIDs involve more than one gene mutations (McCusker & Warrington, 2011; Schroeder, 
Schroeder, & Sheikh, 2004).  PIDs are caused by underlying genetic defects whereas 
secondary immunodeficiencies are caused by other causes, such as viral or bacterial 
infections, malnutrition, immunosuppressive drugs, environment stress, age extremity 
such as prematurity or aging, surgery or metabolic diseases (Chinen & Shearer, 2008). 
PIDs are rare diseases with an overall estimated prevalence of about 2.3 in 
100,000 people, as reported in a Japanese series (Ishimura et al., 2011).  A much higher 
prevalence is observed among populations with high consanguinity rates especially if 
the disease is caused by autosomal recessive inheritance (Hamamy, Masri, Al-Hadidy, 
& Ajlouni, 2007).  Besides that, ethnicity difference may result in different prevalence 
for the similar disease.  For instance, selective IgA deficiency is common PIDs in 
Caucasians, accounting for 1 in 500 individuals, whereas selective IgA deficiency is 
rare among Japanese population, accounting for approximately 1 in 18,000 individuals 
(Cunningham-Rundles & Ponda, 2005).   
Traditionally, the classification of PIDs are based on the component of the 
immune system which is affected (Notarangelo et al., 2009).  However, in some cases, 
defects in the same gene can result in different clinical phenotypes, and defects in 
different genes can lead to the same clinical phenotypes (Maggina & Gennery, 2013).  
This makes the classification difficult to fit all needs.  To date, more than 180 different 
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forms of PIDs were characterized and classified into eight groups (Al-Herz et al., 2011; 
Maggina & Gennery, 2013).  This classification includes combined immunodeficiencies 
(CIDs), well-defined syndromes with immunodeficiency, predominantly antibody 
deficiencies, diseases of immune dysregulation, congenital defects of phagocytes, 
defects in innate immunity, autoinflammatory disorders, and complement deficiencies 
(Al-Herz et al., 2011), as listed in Table 2.1.   
The main characteristic of PID patients is an enhanced susceptibility to 
particular infectious pathogens.  The type of pathogen correlates to the type of 
immunological defect that is present.  For example, patients with combined 
immunodeficiencies tend to suffer from recurrent infections caused by opportunistic 
pathogens such as Candida albicans, Pneumocystis jiroveci or cytomegalovirus, 
whereas, patients with phagocytes disorders tend to have severe pyogenic (pus-like) 
bacterial and fungal infections of the skin, respiratory tract, internal organs, and mouth 
(McCusker & Warrington, 2011).     
Antibody deficiencies are the most common type of primary 
immunodeficiencies.  A recent paper described the spectrum of PIDs in Malaysia, as 
shown in Figure 2.1.  Predominant antibody deficiency was the commonest among other 
PIDs, accounting for 40.38%, followed by phagocytic defect, 17.3%; combined 
immunodeficiency, 15.38%; other cellular immunodeficiency, 11.5%; other deficiencies, 
9.61%; immune deficiency with secondary or other diseases, 3.8%; and immune 
deficiency associated lymphoproliferation, 1.92% (Noh et al., 2013). 
Other than Malaysia, few papers from Asian countries reported that the 
frequency of antibody deficiencies also accounts for nearly half of the PIDs population.  
For instance, it has been reported that the frequency of antibody deficiencies is 
approximately 40% in Japan (Ishimura et al., 2011), 43% in Hong Kong (Lam, Lee, 
Chan, Ho, & Lau, 2005), 46.2% in Singapore (Lim et al., 2003), 48.2% in China  
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            Table 2.1: The classification of primary immunodeficiencies (PIDs). 
 
Type of PIDs 
1 Combined immunodeficiencies 
2 Well-defined syndromes with immunodeficiency 
3 Predominantly antibody deficiencies 
4 Diseases of immune dysregulation 
5 Congenital defects of phagocyte number, function, or both 
6 Defects in innate immunity 
7 Autoinflammatory disorders 
8 Complement deficiencies 
 
                                                                              (Source: Al-Herz et al., 2011) 
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Figure 2.1: Spectrum of Primary Immunodeficiency in Malaysia. 
 
Note: ‘Pred Ab’ represents predominant antibody defect; ‘comb ID’ represents 
combined immunodeficiency; ‘other cell immunodef’ represents other cellular 
immunodeficiency; ‘Def Phagoc’ represents defective phagocytosis; ‘ID assoc 
lymphopro/ other dis’ represents immunodeficiency associated 
lymphoproliferation; ‘ID c secondary/ other dis’ represents immunodeficiency 
with secondary/ other disease; and ‘other def’ represents other deficiencies. 
  
              (Source: Noh et al., 2013) 
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(Wang et al., 2011), 52.2% in Thailand (Benjasupattananan et al., 2009) and 55.9% in 
Korea (Rhim et al., 2012).  However, a higher frequency of antibody deficiencies was 
observed in Caucasian PIDs.  For example, antibody deficiencies accounts for 78% of 
PIDs in the United States (Joshi, Iyer, Hagan, Sauver, & Boyce, 2009).  More than 20 
different types of antibody deficiencies have been described to date (Al-Herz et al., 
2011) (Table 2.2).  Typical categories of antibody deficiencies include X-linked 
agammaglobulinemia (XLA), common variable immunodeficiencies, hyper IgM 
syndrome and selective IgA deficiency (Driessen & Burg, 2011). 
Children suffering PIDs due to B cell defects tend to present at around 4 to 12  
months of age when mother’s passively transferred immunity is on the wane (Lim & 
Elenitoba-Johnson, 2004; McCusker & Warrington, 2011).  Patients with B cell defects 
may have too few antibody-producing B cells or non- functional B cells leaving them 
susceptible to a wide range of infections.  They frequently present with recurrent 
respiratory tract infections caused mainly by extracellular encapsulated bacteria such as 
Streptococcus pneumoniae or Haemophilus influenzae (McCusker & Warrington, 2011).  
In addition to bacterial infections, patients with antibody deficiencies are susceptible to 
enteroviral infections and Gardia lamblia protozoa infection (Notarangelo, 2010). 
 
2.2   B cell development  
 
During gestation, B cells develop from committed precursors in the fetal liver.  
After birth, B cells generation takes place in the bone marrow (Abbas, Lichtman, & 
Pillai, 2010).  Early B cell development includes the development from pro-B cell to 
pre-B cells.  This process does not require antigen contact and takes place in the bone 
marrow (Figure 2.2).  Further development of pre-B cells to immature B cells occurs in 
the bone marrow.  However, maturation of B cells in the periphery is antigen-dependent. 
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Table 2.2: Classification of predominantly antibody deficiencies. 
 Diseases 
1 Severe reduction in all serum immunoglobulin isotypes with profoundly 
decreased or absent B cells 
(a) BTK deficiency (X-linked agammaglobulinemia) 
(b) µ heavy chain deficiency 
(c) λ5 deficiency 
(d) Ig deficiency 
(e) Ig deficiency 
(f) BLNK deficiency 
(g) Thymoma with immunodeficiency 
(h) Myelodysplasia with hypogammaglobulinemia 
 
2 Severe reduction in at least 2 serum immunoglobulin isotypes with normal or 
low number of B cells 
(a) Common variable immunodeficiency 
(b) ICOS deficiency 
(c) CD19 deficiency 
(d) CD81 deficiency 
(e) CD20 deficiency 
(f) TACI deficiency 
(g) BAFF receptor deficiency 
 
3 Severe reduction in serum IgG and IgA with normal/ elevated IgM and normal 
numbers of B cells 
(a) CD40L deficiency 
(b) CD40 deficiency 
(c) AID deficiency 
(d) UNG deficiency 
 
4 Isotype or light chain deficiencies with normal numbers of B cells 
(a) Ig heavy chain mutations and deletions 
(b) Κ chain deficiency 
(c) Isolated IgG subclass deficiency 
(d) IgA with IgG subclass deficiency 
(e) Selective IgA deficiency 
 
5 Specific antibody deficiency with normal Ig concentrations and normal 
numbers of B cells 
 
6 Transient hypogammaglobulinemia of infancy with normal numbers of B cells 
 
              
   (Source: Al-Herz et al., 2011)  
10 
 
 
 
 
 
Figure 2.2: Overview of B cell development. 
 
 (Source: Kurosaki, Shinohara, & Baba, 2009) 
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During early B cell development, pro-B cells undergo VDJ rearrangement of the 
immunoglobulin heavy chain (µHC) loci (Zhang, Srivastava, & Lu, 2004).  Pre-B cell 
receptor (pre-BCR) complex is expressed after the completion of µHC gene 
rearrangement (Geier & Schlissel, 2006).  Expression of µHC leads to pre-B cell 
expansion.   
Pre-B cell receptor (pre-BCR) is expressed on the surface of pre-B cell.  Pre-
BCR complex consists of two µ heavy chains and two surrogate light chains (Figure 
2.3).  The surrogate light chains are composed of VpreB protein and λ5 protein.  Vpre B 
protein is homologous to a light chain V domain, whereas λ5 protein is covalently 
attached to the µ heavy chain by disulfide bond.  The pre-BCR is also associated with 
the signal transducing protein Igα (CD79a) and Igβ (CD79b) which are expressed on all 
B cells (Fried & Bonilla, 2009).   
Figure 2.4 shows the proximal B-cell receptor-mediated signaling pathways.  
Upon the binding of extracellular antigen with BCR, a series of signal transduction will 
be initiated.  The cytoplasmic domains of Igα and Igβ contain immunoreceptor tyrosine-
based activation motifs (ITAMs) provides a docking site for the Syk kinase, Src family 
kinases (Fyn, Lyn, and Blk), the Tec family kinase (Bruton tyrosine kinase), the adaptor 
proteins Grb2 and B cell linker protein (BLNK) (Geier & Schlissel, 2006).  Once Syk 
binds to the Igα ITAM, and the B-cell linker protein (BLNK) will activate Btk signaling 
pathway, which then activates phospholipase C (PLC-2) and leads to calcium flux 
(Wang & Clark, 2003).  In the presence of calcium, protein kinase C (PKC-β) will be 
activated, which then results in the activation of nuclear factor-ΚB (NF-ΚB) in the 
antigen-stimulated B cells.  These signaling cascades eventually lead to the activation of 
transcription factors which triggers B cell proliferation and differentiation (Abbas et al., 
2010).  Mutation in the BTK gene causes early arrest of B cell development, resulting in 
X-linked agammaglobulinemia (XLA).  Apart from BTK gene mutation, mutations in 
12 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Schematic representation of (a) the BCR and (b) the pre-BCR.  The 
signaling molecules, Ig/, associated with both the pre-BCR and BCR are shown.  
Both BCR and pre-BCR are membrane-bound receptors. 
 
                           (Source: modified from Mårtensson, Keenan, & Licence, 2007) 
 
 
 
 
 
 
 
 
membrane 
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Figure 2.4: Proximal B-cell receptor-mediated signaling pathways.  After binding 
to antigen, the immunoglobulin Igα and Igβ cytoplasmic tails are phosphorylated 
on the immunoreceptor tyrosine-based activation motif (ITAM) tyrosines by Src-
family tyrosine kinases (SFTKs) and/ or Syk.  Syk then binds to the Igα ITAM, 
and the B-cell linker protein (BLNK) binds to tyrosine 204 of Igα.  This activates 
multiple signaling pathways, including: Btk, which activates phospholipase C 
(PLC-2 and leads to calcium flux (blue) and protein kinase C (PKC) activation 
(green); Grb2, which activates the Ras/ Raf/ mitogen-activated protein kinase 
(MEK) extracellular signal-regulated kinase (ERK) pathway (green); and Vav, 
which activates the Rac/Rho/Cdc42 pathway and results both in cytoskeletal 
rearrangement (maroon) and c-Jun N-terminal protein kinase (JNK) activation 
(green).  The SFTKs themselves activate nuclear factor-ΚB (NF- ΚB) (green).  
        (Source: Wang & Clark, 2003) 
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µ-heavy chain (Lopez Granados et al., 2002), λ5 (Miyazaki et al., 1999), Igα (Minegishi 
et al., 1999; Wang et al., 2002),  Igβ (Ferrari et al., 2007) and BLNK (Pappu et al., 1999) 
gene have been reported in patients with agammaglobulinemia.  In bone marrow, upon 
light chain locus rearrangement, pre-B cells develop into immature B cells where heavy 
and light chain are co-expressed on the cell surface, in association with Ig and Ig, to 
form antigen-specific surface receptor (Wang & Clark, 2003).  BCR consists of the µ 
heavy chains and light chain.  The µ heavy chains are composed of the variable region 
(VH) and constant region (CH1-3), whereas the light Κ or λ chains are composed of a 
variable region (VL) and a constant region (CL) (Figure 2.3).  These variable regions are 
binding site for specific antigens.   
In bone marrow, the immature B cells may encounter high avidity antigens, such 
as multivalent self-antigens.  However, they do not proliferate and differentiate in the 
response to self-antigens.  Instead, a process called negative selection occurs.  During 
negative selection, immature B cells which recognize and react with self-antigens (auto-
reactive immature B cells) may undergo receptor editing, cell death, or functional 
unresponsiveness instead of activation (Abbas et al., 2010).    Therefore, only those 
immature B cells that are non-reactive to self-antigens leave the bone marrow and 
further differentiate to mature B cells in the periphery (Pillai & Cariappa, 2009). 
In periphery, immature B cells will develop into either one of three different B-
cell subsets, which are B-1 B cells, marginal zone B-2 B cells or follicular B-2 B cells 
(Figure 2.5).  B-1 B cells are derived from fetal liver stem cells.  B-1 cells undergo 
renewal and reside in the periphery such as peritoneum and mucosal sites.  They are 
able to elicit early T-independent humoral immune responses.  B-1 cells are able to 
secrete natural antibodies which act against microbial polysaccharides and lipids in the 
gut, peritoneum or mucosal sites (Abbas et al., 2010; LeBien & Tedder, 2008).   
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Figure 2.5: B cell subsets.  (A) The B-1 lineage is derived from fetal liver-derived 
stem cells.  (B)  B-2 lineage is derived from bone marrow precursors.  Follicular B 
cells are circulating lymphocytes, while marginal zone B cells reside primarily in the 
spleen. 
 
                (Source: Abbas et al., 2010) 
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On the other hands, B-2 B cells are derived from the bone marrow precursors, 
and developed into either follicular B-2 B cells or marginal zone B-2 B cells in the 
spleen (LeBien & Tedder, 2008).  Majority of the circulating mature B cells are 
follicular B cells due to its ability to migrate from one lymphoid organ to the next 
lymphoid organ.  Follicular B cells respond to protein antigens, which require helper T-
cells collaboration, undergo germinal centre reactions, and develop to memory cells.  
Whereas, marginal zone B cells reside primarily in the marginal zone of the spleen 
(Pillai & Cariappa, 2009).  Marginal zone B cells act against blood-borne 
polysaccharides, in T-cell-independent manner, which occurs in the marginal zone of 
the spleen (Martin, Oliver, & Kearney, 2001).  
During a primary immune response, a number of naive B cell, such as follicular 
B cells, are activated and experience clonal expansion followed by the generation of 
short-lived plasma cells which secrete low affinity antibodies, IgM.  These antibodies 
are the first defense against the antigen (Wols, 2006).  Meanwhile, a number of naive B 
cells experience a further diversification of its antibody repertoire through class switch 
recombination (CSR) or somatic hypermutation (SHM), where these processes are T-
cell dependent, in the peripheral lymphoid organs.  The outcomes of these events are 
generation of different immunoglobulin isotypes depending on the type of antigens 
encountered and an increase in high-affinity antibodies.  These antibodies are able to 
eliminate microbes more efficiently (Fried & Bonilla, 2009).   
In the meantime, a number of naive mature B cells differentiate into memory 
cells in the germinal center.  During a repeat infection by the same antigen, these 
memory B cells are able to differentiate into antibody-secreting plasma cells rapidly.  
These plasma cells are able to produce high-affinity, isotype-switched antibody (IgG, 
IgM, IgA, or IgE) in a faster and greater magnitude.   
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2.3  X-linked agammaglobulinemia (XLA) 
 
XLA was the firstly described immunodeficiencies by Bruton in 1952 (Bruton, 
1952).  Bruton reported an eight year-old boy suffered from recurrent infections and 
sepsis which were caused by pneumococcus, had no gammaglobulin fraction in his 
serum when tested with protein electrophoresis.  The boy was then treated with monthly 
intramuscular injections of human gamma globulin and he demonstrated a significant 
clinical improvement.  There was no family history of other affected males in his family.  
However, in the next few years, patients with the similar clinical phenotypes were 
studied and noted that most affected patients were males.  This finding suggested that 
Bruton’s agammaglobulinemia was inherited in an X-linked pattern (Elphinstone, 
Wickes, & Anderson, 1956; O’Brien & Sereda, 1956) 
The causative gene of XLA, BTK gene, was identified in 1993 (Vetrie et al., 
1993).  The mutation in BTK gene causes an arrest in the early B cell differentiation 
where it blocks the differentiation of pre-B cells into circulating, mature B cells and 
plasma cells.  Affected males have normal number of pre-B cells in the bone marrow 
but reduced in pre-B-II cells, immature B and mature B cells stages (Nomura et al., 
2000; Noordzij, et al., 2002).   
Since the patients with XLA have low or no circulating B cells and markedly 
reduced immunoglobulin isotypes in the serum (López-Granados, Pérez de Diego, 
Ferreira Cerdán, Fontán Casariego, & García Rodríguez, 2005), they are susceptible to 
recurrent pyogenic bacterial infections (Cunningham-Rundles & Ponda, 2005).  
Pneumonia, upper respiratory tract infections, sinusitis and otitis media are the most 
common clinical presentations in XLA patients (Noh et al., 2013; Wang et al., 2009).  
Other prevalent clinical problems present among patients with XLA
 
are diarrhea, 
arthritis, skin infections, meningitis/ encephalitis, conjunctivitis, osteomyelitis, sepsis, 
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hepatitis, and enteroviral infections (Gaspar & Kinnon, 2001; Lee et al., 2009; Zhang et 
al., 2010).  Vaccine-associated polio has been reported in few XLA patients (Lee et al., 
2009; Winkelstein et al., 2006).  Hence, immunoglobulin replacement therapy via 
intravenous or subcutaneous route must be given to patients with XLA to protect them 
from severe recurrent infections (Maarschalk-Ellerbroek, Hoepelman, & Ellerbroek, 
2011).   
According to the Pan-American Group for Immunodeficiency (PAGID) and the 
European Society for Immunodeficiencies (ESID), the definitive diagnostic criteria for 
XLA are male patient with less than 2% circulating CD19
+
 B cells along with either a 
mutation in BTK gene; absent BTK mRNA in neutrophils or monocytes; absent BTK 
protein in monocytes or platelets; or a positive family history (Conley, Notarangelo, & 
Etzioni, 1999).  Probable diagnostic criteria of XLA are early onset of recurrent 
bacterial infections, hypogammaglobulinemia, absent isohemagglutinins and/or poor 
response to vaccines (Conley et al., 1999). 
The prevalence of XLA varies from country to country.  X-linked 
agammaglobulinemia (XLA) was reported with an estimated prevalence of 1:200,000 
live births, in a BTK database (Valiaho, Smith & Vihinen, 2006).  Recently, Rhim et al. 
(2012) reported that the estimated prevalence of X-linked agammaglobulinemia (XLA) 
was 1.06 per one million of Korean populations.   
 
2.3.1 Molecular basis of XLA 
The BTK gene is located at the long arm of chromosome X, Xq21.3-Xq22 and 
codes for a 659 amino-acid protein (Vetrie et al., 1993).  This gene comprises 19 exons 
which span over 37.5kb of genomic DNA (Gaspar & Kinnon, 2001).   
Up to 2007, 620 unique mutations from 974 unrelated families have been 
recorded in a BTK database (Valiaho et al., 2006).  These mutations vary in type and 
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are scattered throughout all domains of the BTK protein.  They can be categorized as 32% 
missense mutations, 12% nonsense mutations, 27% deletions, 8% insertions, 19% splice 
site mutations, 1% multiple mutations, and 1% upstream mutation (Valiaho et al., 2006).   
  Besides BTKbase, another web-based database on primary immunodeficiency 
diseases has been set up by Japanese group in 2006, namely Resource of Asian Primary 
Immunodeficiency Diseases (RAPID).  This database enables users access to gene-
specific PID and protein information (Keerthikumar et al., 2009).    
 
2.3.2   Cell biology of BTK protein  
Bruton’s tyrosine kinase (BTK) gene encodes for BTK protein.  BTK protein is 
expressed in all the stages of B cells except for plasma cells (Gaspar & Kinnon, 2001).  
BTK is also expressed in monocytes (Futatani et al., 1998) and platelets (Futatani, 
Watanabe, Baba, Tsukada, & Ochs, 2001).  However, BTK protein is not expressed in T 
cells, NK cells and neutrophils (Futatani et al., 1998).    
BTK protein belongs to a family of cytoplasmic tyrosine kinases, but it is 
different from the Src family kinases as it lacks the amino-terminal myristylation signal 
crucial for post-translational modification and membrane localization (Gaspar & 
Kinnon, 2001). The BTK protein is involved in signal transduction which is important 
for B cell differentiation, development and signaling (Mohamed et al., 2009).  It 
consists of five distinct structural domains, which include a pleckstrin homology (PH) 
domain, followed by a Tec homology (TH) domain, a Src homology 3 (SH3) domain, a 
SH2 domain, and a catalytic kinase (SH1) domain (Gaspar & Kinnon, 2001).  The PH, 
TH, SH3 and SH2 domains are important for protein-protein interactions while the 
kinase domain is necessary for catalytic activity
 
(Gaspar & Kinnon, 2001).   
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2.3.3   Roles of Bruton’s tyrosine kinase protein in B cell development  
Mutations in BTK gene lead to the defects in the early B cell development.  The 
roles of BTK protein were studied in a mice model with BTK gene mutation, E41K 
strain (Maas, Dingjan, Grosveld, & Hendriks, 1999).  It was demonstrated that BTK 
was not required in the development of pre-BCR, but it may be involved in the 
immunoglobulin light chain expression signaling in the pre-B cells (Figure 2.6).  BTK 
was also involved in the central tolerance in which the auto-reactive immature B cells 
were removed in the bone marrow.   
Furthermore, in periphery, BTK might mediate signaling involved in follicular 
entry where auto-reactive periphery immature B cells would be inhibited from follicles 
entry.  In addition, BTK played an important role in the survival and development of 
immature B cells into long-lived recirculating B cells.  Last but not least, BTK 
activation may induce terminal differentiation of plasma cells (Maas & Hendriks, 2001). 
 
2.3.4   Diagnostic tests for XLA 
Clinical history, physical examination and family history are useful in 
identifying PIDs, and further laboratory investigations are important to confirm the 
diagnosis.  The initial investigation of patients with suspected antibody deficiencies 
involves the measurement of serum IgA, IgG and IgM.  Patients with very low serum 
immunoglobulin levels may be an indication of antibody deficiencies.  Enumeration of 
lymphocyte subsets using flow cytometry measures CD19
+
 B cells in the peripheral 
blood.  Patients with classical XLA have markedly reduced B cells numbers, with less 
than 2% of CD19
+
 B cells in the peripheral blood ( Lee et al., 2009).  However, a recent 
study showed that patients with specific mutation in BTK gene could have normal or 
near-normal B cell numbers or absent of peripheral B cell numbers (Tao, Boyd, Gonye, 
Malone, & Schwaber, 2000).  Therefore, enumeration of B cell alone could not be the 
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Figure 2.6: Roles of BTK protein in B cell development. 
 
(Source: modified from Maas & Hendriks, 2001)
 
 
 
 
 
 
Requires signaling from BTK  
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definitive diagnostic tool for XLA.   
Low number or absence of B cell in XLA patient is caused by deficient BTK 
protein expression.  Few studies showed that BTK protein is also expressed in 
monocytes and platelets (Futatani et al., 1998, 2001).  Since XLA patients are deficient 
in B cell number but have normal monocytes and platelet numbers, BTK expression can 
be analyzed from monocytes or platelets.  In 1998, a rapid flow cytometric analysis of 
monocyte BTK protein expression was introduced by Futatani et al.  Since then, this test 
has been then widely used for diagnosing XLA.  Most patients with XLA have deficient 
BTK expression in their monocytes and B cells (Futatani et al., 1998; Kanegane et al., 
2001; López-Granados et al., 2005).  However, some patients with missense mutations 
in the BTK gene has been reported to express BTK protein in their B cells, but the 
function was at fault  (Perez de Diego et al., 2008).  Therefore, XLA should not be 
excluded in antibody deficiency suspected with positive BTK expression until a genetic 
analysis of BTK gene is carried out.  In other words, the definitive diagnosis of XLA 
remains genetic analysis of BTK gene (Ameratunga, Woon, Neas, & Love, 2010; 
Hashimoto et al., 1996; Vorechovsky et al., 1995; Zhang et al., 2010). 
 
2.3.5   Clinical management of XLA 
Antibody deficiency as well as X-linked agammaglobulinemia requires 
immunoglobulin replacement therapy via intravenous or subcutaneous route (Gaspar & 
Kinnon, 2001).  Both intravenous and subcutaneous route appear to be safe and have 
comparable efficacy on the prevention and treatment of infections and also earlier 
monitoring for disease complications (Maarschalk-Ellerbroek et al., 2011; Notarangelo, 
2010).  A recent study showed that some patients were still susceptible to respiratory 
tract infections especially pneumonia despite immunoglobulin replacement therapy 
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(Plebani et al., 2002).  This may be due to insufficient residual serum IgG or lack of 
transport of IgG to the mucosal surface site to provide immunity.   
The combination of immunoglobulin replacement therapy and antibiotic 
prophylaxis is effective in treating chronic infections such as chronic sinusitis or 
bronchiectasis (Fried & Bonilla, 2009).  However, these current treatments are not only 
life-long treatments but, they are also not curative.  Other alternative such as lentiviral-
mediated gene therapy (Conley, Rohrer, Rapalus, Boylin, & Minegishi, 2000; Hendriks, 
Bredius, Pike-Overzet, & Staal, 2011) and hematopoietic stem cell transplantation  
(Conley et al., 2005) has been introduced to treat XLA, but these procedures comes with 
different types of risks that could affect the patients’ quality of life.  Therefore, it is 
crucial that an accurate diagnosis of XLA be made prior to these risky procedures. 
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3.0 METHODOLOGY 
 
3.1 Study subjects  
 
The index case was a seven year old Malay boy, who was referred from 
Paediatrics Institute, Kuala Lumpur General Hospital.  The patient had a history of 
recurrent pyogenic infections since he was one year old.   He had recurrent otitis media 
and was admitted almost every year for recurrent bronchopneumonia that usually had 
slow response to antibiotics treatment.  Moreover, he was also admitted once for 
influenza A viral infection.   
At six years and eight months of age, he was admitted to the hospital with 
another episode of bronchopneumonia, serial chest X-ray tests showed recurrent middle 
lobe consolidation.   Besides that, he had episodes of wheezing, suggestive of asthma, 
therefore was started on metered dose inhaler prophylaxis.  His asthma was well 
controlled after started on inhalers.  After the treatment, his symptom was more of 
prolonged productive cough especially in the morning which is the symptom of 
bronchiectasis rather than asthma. 
Physical examination showed a failure to thrive without clubbing but pectus 
carinatum was observed.  Respiratory examination revealed crepitations with minimal 
rhonchi.  No hepatosplenomegaly or enlarged lymph nodes were observed.    
High resolution computed tomography of the thorax showed features of early 
bronchiectasis.  Based on his clinical and laboratory findings (as described in chapter 4), 
clinical diagnosis of XLA with bronchiectasis was made.   
He was then started on three-weekly IVIg therapy at the age of six years and 
nine months old.  Since then, he remained well and suffered no further recurrent episode 
of pneumonia.   
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3.2 Blood samples  
 
Blood samples in EDTA-coagulant (9 ml) were collected from the patient, his 
mother, his sister and a normal control with informed consent.  This study was approved 
by the institutional review board of Institute for Medical Research and the Medical 
Research Ethics Committee, Ministry of Health, Malaysia. 
 
3.3 Flow cytometric assay  
 
This assay was set up to investigate monocyte Bruton’s tyrosine kinase (BTK) 
protein expression in study subjects.  Cell surface staining of monocytes was performed 
prior to intracellular BTK staining.  Intracellular staining of BTK protein was performed 
with minor modifications according to the manufacturer’s protocol (BD Biosciences, 
San Diego, CA, USA).  Firstly, Blood (2 ml) from patient, mother, sister and a normal 
control was collected in a tube with ETDA anticoagulant.   A volume of 10 µl of surface 
marker PE-conjugated anti-human CD14 (BD Pharmingen
TM
, USA) was added into 
each tube with 100 µl of whole blood and mixed briefly.  These tubes were then 
incubated for 15 minutes at room temperature, in the dark.  After incubation, 2 ml of 
pre-warmed Lyse/fix buffer was added into each tube.  Cells was mixed by vortexing 
and then incubated at 37
o
C water bath for 10 minutes.  After that, cells were centrifuged 
at 500 g for 3 minutes and the supernatant was removed.  Pellets were washed with 2 ml 
PBS and centrifuged at 500 g for 3 minutes.  Supernatant was then removed.  The tubes 
were vortexed to loosen the pellet.  The cells were then permeabilized by adding 1 ml of 
BD phosflow Perm buffer II and incubated for 20 minutes on ice, in the dark.  Cells 
were washed twice with 2 ml of PBS.  Cells were centrifuged at 500 g for 3 minutes and 
supernatant was removed.  Cells were resuspended in 100 µl BD Pharmingen
TM 
stain 
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buffer.  A volume of 10 µl of AlexaFluor® 647 conjugated mouse IgG2a, Κ isotype 
control (BD Phosflow
TM
, USA) or AlexaFluor® 647 conjugated BTK-antibodies (clone 
53/BTK) (BD Phosflow
TM
, USA) were added to each tube, respectively.  The 
monoclonal antibody BTK clone used in this experiment was designed to target N-
terminal of the BTK protein, as stated by the manufacturer.  The tubes were vortexed 
gently and then incubated at room temperature for 30 minutes in the dark.  Cells were 
centrifuged at 500 g for 3 minutes.  Then, cells were washed once with 2 ml PBS, 
centrifuged at 500 g for 3 minutes and then supernatant was removed.  BD 
Pharmingen
TM 
stain buffer (500 µl) was then added into the tube with pellet prior to 
flow cytometric assay.  The monocyte BTK expression was analyzed on flow cytometer 
BD FACSCalibur using BD CellQuest
TM
 Pro software.  Two thousand monocytes were 
gated from side scatter versus CD14-PE plot.  The expression of BTK protein was 
further analysed from the gated monocyte population.  
 
3.4 RNA extraction 
 
RNA was isolated from whole blood using the QIAamp RNA blood mini kit 
according to manufacturer’s protocol (Qiagen GmbH, Hilden, Germany).  One mililitre 
(ml) of human whole blood with EDTA coagulant was mixed with 5 ml of EL Buffer in 
a falcon tube.  The tube was incubated for 15 minutes on ice.  While incubating, the 
tube was mixed by vortexing briefly for two times.  Then, the tube was centrifuged at 
400 g for 10 minutes at 4
o
C, and the supernatant was discarded completely.  A pellet 
was formed after centrifugation.  Two ml of EL Buffer was added to the cell pellet.  The 
cells were resuspended by vortexing briefly.  The tube was then centrifuge at 450 g for 
10 minutes at 4
o
C, and the supernatant was discarded completely.  Seven hundred 
microliter (µl) RLT Buffer with beta-mercaptoethanol was added to pelleted leukocytes 
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and vortex to mix.  The lysate was pipetted directly into a QIAshredder spin column in a 
2 ml collection tube and centrifuged for 2 minutes at maximum speed to homogenize.  
QIAshredder spin column was discarded and homogenized lysate was saved.  A volume 
of 700 µl of 70% ethanol was added to the homogenized lysate and mixed by pipetting.  
Sample was pipetted carefully into a new QIAamp spin column in a 2 ml collection tube 
without moistening the rim.  The spin column was then centrifuged for 15 seconds at 
8,000 g.  The QIAamp spin column was transferred into a new 2 ml collection tube.  
RW1 Buffer 700 µl was applied to the QIAamp spin column and centrifuged for 15 
seconds at 8,000 g to wash.  QIAamp spin column was placed in a new 2 ml collection 
tube.  RPE Buffer 500 µl was pipetted into the QIAamp spin column and centrifuged for 
15 seconds at 8,000 g.  The QIAamp spin column was opened carefully and 500 µl of 
RPE buffer was added.  The cap was closed and centrifuged at 15,000 g for 3 minutes.  
The QIAamp spin column was placed in a new 2 ml collection tube and the old 
collection tube with the filtrate was discarded.  The spin column was centrifuged at full 
speed for 1 minute.  QIAamp spin column was transferred into a 1.5 ml microcentrifuge 
tube and 50 µl of RNase-free water was pipetted directly onto the QIAamp membrane 
and centrifuged for 1 minute at 8,000 g to elute the RNA.  Total RNA concentration was 
quantitated by using NanoDrop N1000 spectrophotometer.  
 
3.5 First-Strand cDNA synthesis 
 
In order to reverse transcribe total RNA (1 µg) into its complementary DNA 
strand (cDNA) using SuperScript® II Reverse Transcriptase kit (Invitrogen, USA), a 
total volume of 15 µl consisting of 1 µl of random primers (500 µg/ml) and 1 µg of 
RNA was prepared.  Sterile nuclease free water was added to make final volume up to 
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15 µl.  The mixture was then incubated in a thermal cycler at 70
o
C for 5 minutes and 
quick chilled at 4
o
C.   
While waiting for the incubation, a master mix cocktail was prepared by adding 
the following reagents to the final volume of 24 µl;  8 µl of  5X First-Strand buffer, 4 µl 
of 0.1M DTT, 4 µl of 10 mM dNTP,1 µl of recombinant RNasin® ribonclease inhibitor 
(40 U/µl), and 7 µl of sterile nuclease free water.  The tubes were collected after a quick 
chill.  One microliter of 200 U/µl of superscript® II Reverse Transcriptase and 24 µl of 
master mix cocktail was then added into each incubated tube to make the final volume 
to 40 µl.  The reaction tubes were then heated at 42
o
C for 1 hour, followed by 90
o
C for 
5 minutes and 4
o
C until the tubes were collected.  The tubes were stored at -20
o
C until 
future use.  
 
3.6 PCR of cDNA  
 
A set of primer covering actin gene was used as a housekeeping gene to show 
presence of cDNA template before proceeding with amplification of BTK gene.  The 
sequence of primer set used to amplify actin gene is shown in Table 3.1.   
When there was presence of PCR products as amplified by the actin primer set, 
the similar cDNA template was used for BTK gene amplification.  The BTK gene was 
amplified from the cDNA with seven overlapping PCR primer sets which covered all 
the 19 exons of BTK gene (as shown in Table 3.2) using PCR conditions described 
previously (Hashimoto et al., 1996).  These seven sets of primers were used to screen 
for BTK gene mutations at the cDNA level.  The normal sequence of 19 exons of human 
BTK gene with highlighted primer sets is shown in Figure 3.1.   
The PCR was performed in a volume of 50 µl consisting 1 μl cDNA, 4.5 µl of 
25 mmol/L MgCl2, 4 μl of 10x PCR buffer, 1.25 µl (10 µM) of forward primer, 1.25 µl  
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Table 3.1: Primers used for actin gene amplification from cDNA. 
 Primer 
name 
     5’-3’ primer sequence Fragment 
length 
 
 
Forward primer 
 
ActinF: 
 
AGCGGGAAATCGTGCGTG 
 
 
307 bp 
Reverse primer ActinR CAGGGTACATGGTGGTGCC  
 
(Source: Thomas, Samanta, & Fikrig, 2008) 
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Table 3.2: Primers used for BTK gene amplification from cDNA. 
Primer 
set 
Forward primer/Sense primer (5’-3’) /  
Reverse primer/ Antisense Primer(5’-3’) 
Fragment 
position* 
Fragment 
length 
 
1 BTK1F:    AGCTACCTGCATTAAGTCAG     
 
BTK3R:   CTTCTCGGAATCTGTTTTC 
 
 
137-438 
 
302 bp 
2 BTK3F:   CACTTGTGTTGAAACAGTGG 
 
BTK7R:  TCCGGTGAGAACTCCCAGGT 
 
 
376-740 
 
365 bp 
3 BTK6F:     ATGCTATGGGCTGCCAAATT 
 
BTK10R:   TTTAGCAGTTGCTCAGCCTG 
 
 
675-1080 
 
406 bp 
4 BTK9F:     GTATGAGTGGTATTCCAAAC 
 
BTK14R:   GGTCCTTTGGATCAATTTCC 
 
 
1029-1397 
 
369 bp 
5 BTK13F:   GCAGGCCTGGGATACGGATC 
 
BTK15R:   GGTGAAGGAACTGCTTTGAC 
 
 
1355-1751 
 
397 bp 
6 BTK15F:   ATGGCTGCCTCCTGAACTAC 
 
BTK17R:   TGTCAGATTTGCTGCTGAAC 
 
 
1629-1931 
 
303 bp 
7 BTK17F:   CGGAAGTCCTGATGTATAGC 
 
BTK19R:   CAAGAAGCTTATTGGCGAGC 
 
 
1890-2193 
 
304 bp 
 
* The numbering of the nucleotide position follows the nucleotide numbering of the 
reference cDNA sequence with Genebank reference NM_000061.2 (mRNA) 
 
   (Source:  Hashimoto et al., 1996) 
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1   aactgagtgg ctgtgaaagg gtggggtttg ctcagactgt ccttcctctc tggactgtaa       
61  gaatatgtct ccagggccag tgtctgctgc gatcgagtcc caccttccaa gtcctggcat      
121 ctcaatgcat ctgggaagct acctgcatta agtcaggact gagcacacag gtgaactcca      
181 gaaagaagaa gctatggccg cagtgattct ggagagcatc tttctgaagc gatcccaaca      
241 gaaaaagaaa acatcacctc taaacttcaa gaagcgcctg tttctcttga ccgtgcacaa      
301 actctcctac tatgagtatg actttgaacg tgggagaaga ggcagtaaga agggttcaat      
361 agatgttgag aagatcactt gtgttgaaac agtggttcct gaaaaaaatc ctcctccaga      
421 aagacagatt ccgagaagag gtgaagagtc cagtgaaatg gagcaaattt caatcattga      
481 aaggttccct tatcccttcc aggttgtata tgatgaaggg cctctctacg tcttctcccc      
541 aactgaagaa ctaaggaagc ggtggattca ccagctcaaa aacgtaatcc ggtacaacag      
601 tgatctggtt cagaaatatc acccttgctt ctggatcgat gggcagtatc tctgctgctc      
661 tcagacagcc aaaaatgcta tgggctgcca aattttggag aacaggaatg gaagcttaaa      
721 acctgggagt tctcaccgga agacaaaaaa gcctcttccc ccaacgcctg aggaggacca      
781 gatcttgaaa aagccactac cgcctgagcc agcagcagca ccagtctcca caagtgagct      
841 gaaaaaggtt gtggcccttt atgattacat gccaatgaat gcaaatgatc tacagctgcg      
901 gaagggtgat gaatatttta tcttggagga aagcaactta ccatggtgga gagcacgaga      
961 taaaaatggg caggaaggct acattcctag taactatgtc actgaagcag aagactccat     
1021 agaaatgtat gagtggtatt ccaaacacat gactcggagt caggctgagc aactgctaaa     
1081 gcaagagggg aaagaaggag gtttcattgt cagagactcc agcaaagctg gcaaatatac     
1141 agtgtctgtg tttgctaaat ccacagggga ccctcaaggg gtgatacgtc attatgttgt     
1201 gtgttccaca cctcagagcc agtattacct ggctgagaag caccttttca gcaccatccc     
1261 tgagctcatt aactaccatc agcacaactc tgcaggactc atatccaggc caaatatcc     
1321 agtgtctcaa caaaacaaga atgcaccttc cactgcaggc ctgggatacg gatcatggga     
1381 aattgatcca aaggacctga ccttcttgaa ggagctgggg actggacaat ttggggtagt     
1441 gaagtatggg aaatggagag gccagtacga cgtggccatc aagatgatca aagaaggctc     
1501 catgtctgaa gatgaattca ttgaagaagc caaagtcatg atgaatcttt cccatgagaa     
1561 gctggtgcag ttgtatggcg tctgcaccaa gcagcgcccc atcttcatca tcactgagta     
1621 catggccaat ggctgcctcc tgaactacct gagggagatg cgccaccgct tccagactca     
1681 gcagctgcta gagatgtgca aggatgtctg tgaagccatg gaatacctgg agtcaaagca     
1741 gttccttcac cgagacctgg cagctcgaaa ctgtttggta aacgatcaag gagttgttaa     
1801 agtatctgat ttcggcctgt ccaggtatgt cctggatgat gaatacacaa gctcagtagg     
1861 ctccaaattt ccagtccggt ggtccccacc ggaagtcctg atgtatagca agttcagcag     
1921 caaatctgac atttgggctt ttggggtttt gatgtgggaa atttactccc tggggaagat     
1981 gccatatgag agatttacta acagtgagac tgctgaacac attgcccaag gcctacgtct     
2041 ctacaggcct catctggctt cagagaaggt atataccatc atgtacagtt gctggcatga     
2101 gaaagcagat gagcgtccca ctttcaaaat tcttctgagc aatattctag atgtcatgga     
2161 tgaagaatcc tgagctcgcc aataagcttc ttggttctac ttctcttctc cacaagcccc     
2221 aatttcactt tctcagagga aatcccaagc ttaggagccc tggagccttt gtgctcccac     
2281 tcaatacaaa aaggcccctc tctacatctg ggaatgcacc tcttctttga ttccctggga     
2341 tagtggcttc tgagcaaagg ccaagaaatt attgtgcctg aaatttcccg agagaattaa     
2401 gacagactga atttgcgatg aaaatatttt ttaggaggga ggatgtaaat agccgcacaa     
2461 aggggtccaa cagctctttg agtaggcatt tggtagagct tgggggtgtg tgtgtggggg     
2521 tggaccgaat ttggcaagaa tgaaatggtg tcataaagat gggaggggag ggtgttttga     
2581 taaaataaaa ttactagaaa gcttgaaagt c 
Figure 3.1: The normal sequence of 19 exons of human BTK gene with highlighted 
primer sets.  The sequence shown was obtained from Genbank reference NM_000061.2 
(cDNA).  Single line denotes the boundaries of each exon. 
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(10 µM) of reverse primer, 2 µl of 10 mM dNTP mixture, 0.25 μl of GoTaq® Flexi 
DNA polymerase (5 U/µl) (Promega, USA) and sterile nuclease free water added to 
make final volume up to 50 µl.  The mixture was denatured at 94
o
C for 3 minutes, 
followed by 33 cycles at 94
o
C for 30 seconds, at 54
o
C for 30 seconds, and at 72
o
C for 
40 seconds, then with a final extension at 72
o
C for 8 minutes.  The samples were kept at 
4
o
C prior to gel electrophoresis. 
 
3.7 Leukocyte isolation and DNA extraction 
 
 Leukocytes were separated from 5 ml of EDTA blood using Ficoll Hypaque 
(Lymphoprep
TM, 
Axis-shield, Norway) and the DNA was then extracted using the 
QIAamp DNA Blood mini kit (Qiagen GmbH, Hilden, Germany).   
 
3.7.1 Leukocyte isolation 
 A volume of 5 ml of EDTA anti-coagulated whole blood was diluted with 5 ml 
of PBS and mixed well.  A volume of 3.5 ml of lymphoprep
TM 
solution (Axis-shield, 
Norway) was pipetted into two plain tubes, respectively.  The diluted blood (5 ml) was 
layered on the lymphoprep
TM 
solution carefully in each tube and spun at 600 g for 15 
minutes.  The buffy coat layer which was rich with leukocytes was harvested and then 
washed with PBS at 400 g for 5 minutes.  The supernatant was discarded.  The pellet 
was broken by vortexing.  Then, the pellet was washed with PBS at 400 g for 5 minutes.  
The supernatant was aspirated until 200 µl PBS left in the tube.  The tube was vortexed.  
Approximately 100 µl of PBS was added to the tube to rinse the tube.  The tube 
containing 300 µl of PBS which was rich with leukocytes could be kept in 4
o
C 
overnight or proceed with DNA extraction directly.  
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3.7.2 DNA extraction 
 Genomic DNA was isolated from the leukocytes of the patient, mother, sister 
and a normal control, respectively, using QIAamp DNA Blood mini kit, according to 
the manufacturer’s protocol (Qiagen GmbH, Hilden, Germany).  The microfuge 
containing 300 µl of PBS with leukocytes was spun at 1,000 g for 2 minutes.  
Approximately 200 µl of the pellet was transferred into a new microfuge tube.  A 
volume of 20 µl protease was added and mixed well with pipette.  A volume of 200 µl 
of AL Buffer was added and vortexed briefly, then incubated at 56
o
C for 10 minutes.  
After incubation, 200 µl absolute ethanol was added and vortexed briefly.  The sample 
was transferred into a mini spin column with collection tube and spun at 7,000 g for 1 
minute.  The flow through was discarded, 500 µl AW1 buffer was added and the 
column was spun at 7,000 g for 1 minute.    Again, the flow through was discarded, then, 
500 µl AW2 buffer was added and the column was spun at 20,000 g for 3 minutes.  The 
flow through was discarded, and the spin column was then transferred into a clean 
microfuge tube.  AE Buffer 200 µl was added, followed by incubation at room 
temperature for 5 minutes and spun at 7,000 g for 1 minute.  The spin column was then 
discarded.  The microfuge tube was placed in a dry-bath at 96
o
C (Eppendorf, USA) for 
5 minutes to denature the DNA.  Then, the denatured DNA samples were kept on ice 
prior to DNA concentration and purity estimation.  The DNA concentration and purity 
was determined using NanoDrop N1000 spectrophotometer.  The DNA samples were 
then kept in -20
o
C for future use. 
 
3.8 PCR of genomic DNA 
In order to confirm the mutation found at the cDNA level, genomic DNA was 
amplified with respective primers which flanking intron-exon boundaries as listed in 
Table 3.3 using PCR conditions as described previously (Hashimoto et al., 1996).   
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Table 3.3: Primers used for amplification of the BTK gene from genomic DNA. 
 Primer 
name 
5’-3’ primer sequence *Primer 
Position 
Fragment 
length 
 
Forward primer BTKg9F gggaggtgctggatgaactg 31035-31054  
   138 bp 
Reverse primer BTKg9R cagtcaggtgttagaaggtcc 31152-31172  
 
* The numbering of the nucleotide position follows the nucleotide numbering of the 
reference gDNA sequence with Genebank reference NG_009616.1 (gDNA) 
 
(Source: Vorechovsky et al., 1995) 
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The primers used were positioned in the BTK introns which were just upstream and 
downstream of the exon-intron boundaries in order to investigate mutation involving 
invariant splice sites.  
The PCR was performed in a volume of 50 µl consisting 200 ng of gDNA 
template, 4.5 µl of 25 mmol/l MgCl2, 4 μl of 10x PCR buffer, 1.25 µl (10 µM) of 
forward primer, 1.25 µl (10 µM) of reverse primer, 2 µl of 10 mM dNTP mixture, and 
0.25 μl of GoTaq® Flexi DNA polymerase (5 U/µl) (Promega, USA) and sterile 
nuclease free water added to make final volume up to 50 µl.  The mixture was denatured 
at 94
o
C for 3 minutes, followed by 33 cycles at 94
o
C for 30 seconds, at 54
o
C for 30 
seconds, and at 72
o
C for 40 seconds, then with a final extension at 72
o
C for 8 minutes.  
The samples were kept at 4
o
C prior to gel electrophoresis.  
 
3.9 PCR product purification 
 
Following electrophoresis, PCR product was purified using Wizard® SV gel and 
PCR clean-up system kit according to the manufacturer’s protocol (Promega, USA).  
Equal volume of PCR product (40 µl) was added to 40 µl membrane binding solution 
respectively.  SV Minicolumn (provided by the kit) was inserted into a collection tube.  
Prepared PCR product was transferred to the Minicolumn assembly and incubated at 
room temperature for 1 minute.  It was then spun at 16,000 g for 1 minute.  The flow 
through was discarded and Minicolumn was reinserted to the collection tube.  
Membrane Wash Solution containing ethanol (700 µl) was added and the column was 
spun at 16,000 g for 1 minute.  The flow through was discarded and Minicolumn was 
reinserted to the collection tube.  Membrane Wash Solution containing ethanol (500 µl) 
was added and the column was spun at 16,000 g for 5 minutes.  The collection tube was 
emptied and the column assembly was centrifuged for 1 minute.  This time, the 
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microcentrifuge lid was open to allow evaporation of any residual ethanol.  Minicolumn 
was then transferred carefully to a clean 1.5 ml microcentrifuge tube.  Nuclease-Free 
Water (50 µl) was added to the Minicolumn followed by incubation at room 
temperature for 5 minutes.  It was then centrifuged at 16,000 g for 1 minute.  The 
minicolumn was discarded.  The concentration and purity of the purified PCR products 
were quantitated using NanoDrop-1000 spectrophotometer.  An aliquot of purified 
products were then sent for DNA sequencing.  The remaining purified PCR products 
were stored at 4
o
C.    
 
3.10 DNA Sequencing  
 
The purified PCR products were sent to First Base Laboratories (M) Pte Ltd 
where sequencing was carried out using BigDye Terminator v.3 cycle sequencing kit 
(Applied Biosystems, Foster City, CA, USA).  GenBank reference sequence with 
accession number NM_000061.2 (mRNA) and NG_009616.1 (gDNA) were used as 
reference for sequence comparison. 
 
3.11   Protein sequence prediction 
 
The cDNA sequences of each study subject were translated into amino acid 
codon respectively using Expasy translation tool (http://web.expasy.org/translate/).  The 
BTK protein sequences of each study subject were then compared to the reference BTK 
protein sequences, as described in GenBank reference sequence with accession number 
AAB64205.1 (protein).  Both study subject and the reference protein sequences were 
aligned using SDSC Biology workbench online application (http://workbench.sdsc.edu/) 
to facilitate the interpretation of the mutation noted in protein level.  
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4.0 RESULTS 
 
4.1 Patient’s serum immunoglobulin measurement history 
 
Patients with antibody deficiency have very low serum immunoglobulin levels, 
making them susceptible to recurrent infections.  In this study, the patient’s serum 
immunoglobulin measurement history was traced back from the test record book of 
Allergy and Immunology Research Centre, Institute for Medical Research.  Table 4.1 
shows the history of the patient’s serum immunoglobulin levels before and after 
receiving intravenous immunoglobulin replacement therapy.  Few Immunoglobulin 
levels data were not available because the samples were sent to different laboratories for 
measurement or the patient did not turn up.  Serum samples that were collected and 
tested prior to the next IVIg infusion were labelled as ‘pre-IVIg’ level; whereas serum 
samples collected and tested 24-hour or 48-hour after the IVIg infusion were labelled as 
‘post-IVIg’ level.     
Before receiving IVIg treatment, laboratory finding revealed that the patient’s 
serum immunoglobulin levels were lower as compared to that of an age matched child 
(Table 4.1).  He was started on three-weekly IVIg therapy at the age of six years and 
nine months old.  He had low serum IgG level prior to the next infusion during six years 
and nine months old, 47mg/dL.  The serum IgG level started to increase and remained 
within the normal limit of the reference range.  The serum IgG level prior to the next 
infusion (pre-IVIg) was slightly lower than the respective post-IVIg IgG level.  
However, his serum IgA and IgM levels before and after receiving IVIg therapy 
remained lower than lower limit of the reference range.  
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Table 4.1: History of the patient’s serum immunoglobulin levels before and after receiving intravenous immunoglobulin replacement therapy. 
             
            Age 
 
6y9m 6y9m 6y11m 7y2m 7y2m 7y3m 
Reference range 
(mg/dl) 
6-9 years old 
Status Before receiving 
IVIg therapy 
Pre Post Pre Post Pre Post 
(24H) 
Pre Post 
(24H) 
Pre Post 
(24H) 
Post 
(48H) 
 
 
 
IgG 
 
41 47 N.D 483 N.D N.D 1107 754 1244 783 1170 1237 550-1200 
IgA 
 
48 38 N.D 31 N.D N.D 39 37 39 41 19 39 60-170 
IgM 
 
<12 28 N.D 15 N.D N.D 22 12 19 34 35 25 40-95 
 
Note: ‘y’ represents years; ‘m’ represents months; ‘Pre’ represents pre-IVIg; ‘Post’ represents post-IVIg; 24H represents 24 hours after IVIg infusion; 
48H represents 48 hours after IVIg infusion; ‘N.D.’ represents not determined. 
Ig level 
(mg/dL) 
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4.2 Lymphocyte subset immunophenotyping  
 
Lymphocyte subset immunophenotyping using flow cytometry was able to 
determine the absolute count and the percentage values of T-cell subsets (CD3, CD4, 
and CD8), B-cell (CD19) and natural killer cell (CD16 and CD56).  This assay is used 
as a diagnostic and management tool for screening of primary immunodeficiency 
patients with defective of any lymphocyte subsets and also monitoring of the treatment 
progression in acquired immunodeficiency patients.  Patients with XLA have less than 2% 
CD19
+
 B cells in the peripheral blood (Conley, Notarangelo, & Etzioni, 1999).   
Tables 4.2 and 4.3 show the patient’s lymphocyte subset immunophenotyping 
results tested when he was six years and eight months old and seven years and five 
months old, respectively.   
Before receiving IVIg therapy, the patient had no circulating B cells (Table 4.2).  
After receiving IVIg therapy, he was tested again and the results showed that he had 
negligible number of B cells that was 7 cells/ µl B cells (Table 4.3).  Interestingly, the 
percentage and absolute count of total T cells of the patient were slightly higher than a 
normal child with the same age.  His CD4 T helper cells were also slightly higher than a 
child with the same age, but NK cells were slightly lower in the patient (Tables 4.2 and 
4.3).  This phenomenon could be due to compensation of B cell insufficiency. 
 
4.3 Flow cytometric analysis 
 
In general, XLA patients have less than 2% CD19
+
 B cells.  Due to the 
insufficient amount of B cells in XLA patients, for further molecular biology analysis, 
monocytes which are known to express BTK protein were used to determine the BTK  
 
40 
 
 
 
 
 
 
 
Table 4.2: Patient’s lymphocyte subset immunophenotyping was determined at six 
years and eight months old (pre-IVIg treatment). 
    
  
  
 Patient Reference range 
(7-17 years old) 
 
 Percentage 
(%) 
 
Absolute count  
(cells/ µl) 
Percentage 
(%) 
Absolute count 
(cells/ µl) 
Total B cells 
(CD19
+
) 
 
0 
 
0 
 
21-28 700-1300 
Total T cells 
(CD3
+
) 
94 
 
4293 
 
62-69 1800-3000 
T helper cells 
(CD3
+
CD4
+
) 
 
64 
 
2923 
 
30-40 1000-1800 
T cytotoxic 
cells 
(CD3
+
CD8
+
) 
 
26 
 
1188 
 
25-32 800-1500 
Natural killer 
cells 
(CD16
+
CD56
+
) 
 
4 
 
183 
 
8-15 200-600 
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Table 4.3: Patient’s lymphocyte subset immunophenotyping was determined at seven 
years and five months old (post-IVIg treatment). 
   
  
 Patient Reference range 
(7-17 years old) 
 
 Percentage 
(%) 
Absolute count 
(cells/ µl) 
Percentage 
(%) 
Absolute count 
(cells/ µl) 
 
Total B cells 
(CD19
+
) 
 
0 
 
7 
 
21-28 700-1300 
Total T cells 
(CD3
+
) 
93 3110 62-69 1800-3000 
T helper cells 
(CD3
+
CD4
+
) 
 
58 1974 30-40 1000-1800 
T cytotoxic 
cells 
(CD3
+
CD8
+
) 
 
29 992 25-32 800-1500 
Natural killer 
cells 
(CD16
+
CD56
+
) 
 
6 184 8-15 200-600 
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protein expression.  Futatani et al. (1998) reported the use of intracellular staining of 
monocyte BTK protein expression to confirm the diagnosis of XLA where patients with  
XLA have deficient monocyte BTK expression.  In this study, BTK expression was 
analyzed from the gated CD14
+
 stained monocyte population.  As mentioned in the 
methodology section, this antibody used in the experiment was designed to target N-
terminal of BTK protein which means that any mutation at the N-terminal of BTK 
protein could abolish the binding affinity of the antibody to the mutated BTK protein. 
Mouse IgG2a, Κ isotype control was used to assess the level of background staining for 
monocyte BTK expression analysis.  Monocyte BTK expression was defined based on 
isotype control expression.  Mean fluorescence intensity (MFI) is represented by the 
geometrical mean of the gated population, as obtained from the flow cytometric 
histogram statistical analysis.  Figure 4.1 shows the overlay histograms of population 
stained with isotype control and BTK.  The overlapping of BTK peak with isotype 
control peak represents a negative expression.  While a positive expression is 
represented by a separation between isotype control and BTK peak.  In the normal 
control, MFI value of monocyte isotype control expression was 9.  When stained with 
BTK, only one monocyte population was seen and its MFI value was 39. The result 
indicated that 98% of the monocytes in normal control expressed BTK protein (Figure 
4.1).    In contrast, in the patient, MFI value of isotype control expression was 9.  When 
stained with BTK, only one monocyte population with MFI value of 11 was seen.  The 
result indicated that 94% of the monocytes in the patient did not express BTK protein.  
In the mother, MFI value of isotype control expression was 7.  When stained with BTK, 
two distinct populations were seen.  One monocyte population, 62%, had BTK 
expression with MFI value of 29 whereas another monocyte population, 38%, did not 
express BTK (MFI = 10).  In the sister, MFI value of isotype control was 5.  When 
stained with BTK, a continuous population was seen.  In term of percentage, 40% of  
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Figure 4.1: Flow cytometric analysis of monocyte BTK expression in a normal 
control, the patient, his mother and sister.  The red gated population represents 
monocyte population (two thousands events).  The green line indicates the 
monocyte isotype control antibody expression and purple shaded area indicates 
monocyte BTK expression.  MFI values for isotype control expression (9) and 
BTK expression (39) are shown for normal control’s panel.   The percentage in 
the upper right corner indicates the percentage of monocytes expressing BTK 
protein. 
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monocytes expressed BTK protein (MFI = 22) and 60% monocytes did not express 
BTK protein (MFI = 7).   
 
4.4 RT-PCR and sequencing of amplified cDNA products 
 
Mutations in Bruton’s tyrosine kinase (BTK) gene were known to cause XLA.  
In order to investigate the gene mutation in the XLA patient, reverse-transcriptase 
polymerase chain reaction (RT-PCR) of the patient’s cDNA with respective BTK 
primers was performed.   
Figure 4.2 shows the results of RT-PCR analysis of BTK gene using primers 
listed in Table 3.2.  The BTK gene was then amplified using seven sets of overlapping 
primers as described previously (Hashimoto et al., 1996).  The PCR reactions using the 
primer set 1, 2, 4, 5, 6, and 7 (Figure 4.2A) generated fragments that were normal in 
size as compared to the normal control.  All of these products were sequenced and had 
normal sequence as compared to the normal control.  However, PCR products amplified 
from primer set 3 showed abnormal bands on the 2% agarose gel (Figure 4.2A).  Primer 
set 3 consists of an exon 6 forward primer, BTK6F and an exon 10 reverse primer, 
BTK10.  The patient’s cDNA yielded a single shorter product of 343 base pairs (bp), 
while the normal control’s product was 406 bp long.  Amplification of the mother and 
sister’s cDNA yielded both products.  Sequencing of the cDNA PCR products from the 
mother and sister confirmed that the 343 bp product was the same as the patient’s, while 
the 406 bp product was the same as the normal control’s product.  Sequencing showed 
the patient’s cDNA PCR product was shorter due to exon 9 skipping (Figure 4.3).  At 
the meantime, actin gene was used as a housekeeping gene to confirm the presence of 
cDNA template.  RT-PCR of cDNA with a set of actin primers generated a 307 bp 
fragment (Figure 4.2B).   
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Figure 4.2: Agarose gel electrophoresis of RT-PCR products. 
(A) BTK gene fragment amplified by seven sets of overlapping primers.  
Six fragments were normal in size.  * Asterisk indicates the fragments 
amplified by primer set 3, BTK6F-BTK10R, showing products with 
different length in patient, mother and sister. 
(B) actin gene fragment.  
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Exon 8 Exon 10 
Exon 9 Exon 8 
T CC T G C][CCATTTT T ATC T C G TGCTCTCC A CC A T 
A CCA C][CCA T   T T T T AT  CT  C GT  GCT C T CC A CCA T 
Normal 
Control 
Patient 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Direct sequence analysis of RT-PCR products from a normal control 
and the patient.  Reverse sequence is shown.    
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4.5 PCR and sequencing of amplified genomic DNA products 
 
The patient had an exon 9 skipping of the BTK gene in the cDNA level.  In order 
to confirm the mutation and clarify the mechanism of exon skipping, amplification of 
genomic DNA from the study subjects was performed using a set of primers covering 
the relevant exon-intron boundaries.  The forward primer used in this assay was located 
in intron 8 whereas the reverse primer was located in intron 9 respectively, which 
covered exon 9 and both invariant splice sites (Table 3.3).  The direct sequencing of the 
PCR product amplified by this primer set revealed that the first nucleotide of intron 9 
had changed from G>C, in the patient as compared to the normal control (Figure 4.4).  
However, his mother and sister showed both G and C nucleotides at that position 
(Figure 4.4), reflecting that they are heterozygous at this locus. This finding confirmed 
that they were carriers. 
 
4.6 Protein sequence prediction 
 
The sequencing results from the PCR products amplified by seven sets of 
overlapping primers were compiled and the complete coding sequences were translated 
into its respective amino acid by online Expasy nucleotide Translate tool 
(http://web.expasy.org).  Both amino acid sequences were aligned using SDSC biology 
workbench programme (http://workbench.sdsc.edu).   
Complete BTK gene coding sequences of the normal control coded for a protein 
of 659 amino acid residues, whereas the patient’s complete BTK gene coding sequences 
coded for a protein of 638 amino acid residues.  Alignment result shows the patient had 
a deletion of 21 amino acids, which were from 260
th
 amino acid residue until 280
th
 
amino acid residue (Figure 4.5).  This twenty one amino acid residues deletion  
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Figure 4.4: Direct sequence analysis of genomic DNA from a normal 
control, the patient, his mother and sister.  Forward sequence is shown.  
Capital letters represent the sequence of exon 9 and small letters represent 
the intron 9 sequence.  The underlined nucleotides represent the mutation 
point.   
  
Exon 9 Intron 9 
TATGAgtaag 
Normal Control 
Exon 9 Intron 9 
g  c 
TATGActaag 
Patient 
Exon 9 Intron 9 
Heterozygous alleles:  c/g 
TATGAc/gtaag 
Mother 
Exon 9 Intron 9 
Heterozygous alleles:  c/g 
TATGAc/gtaag 
Sister 
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     Figure 4.6: Comparison of amino acid sequences between a normal control and the 
patient. 
Legend:  ":" = Identity;  " "= mismatched, deletion 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Comparison of amino acid sequences between a normal control and 
the patient.  Alignment that is marked by ‘:’ indicates an identical residue in the 
alignment, while alignment that is unmarked indicates a mismatch or deletion in 
the alignment.  
  
Normal Control 
Patient 
Normal Control 
Patient 
Normal Control 
Patient 
Normal Control 
Patient 
Normal Control 
Patient 
Normal Control 
Patient 
Normal Control 
Patient 
Normal Control 
Patient 
Normal Control 
Patient 
Normal Control 
Patient 
Normal Control 
Patient 
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corresponded to the skipping of exon 9.  Among these twenty one amino acid residues, 
nine of these amino acids are located at SH3 domain of the BTK protein (Figure 4.6).   
 
4.7 Pedigree of the patient 
 
Figure 4.7 shows the pedigree of the patient.  The patient was the youngest child 
of a non-consanguineous marriage.  He had an elder sister.  His mother and sister 
appeared healthy; both of them were recruited in this study.  Besides that, he had also 
two maternal aunts who appeared healthy but were inaccessible for this study.  However, 
his mother reported that two maternal uncles died at below two years of age, due to high 
fever with unknown causes.   
 The carrier status of the mother (II-3) and sister (III-1) in this family was ruled 
out and confirmed in this study by the combination of flow cytometric assay (Figure 4.1) 
and genetic study (Figures 4.2 and 4.4).       
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Figure 4.6: Human BTK protein sequence from Swiss-Prot database with accession 
number Q06187. Each domain is boxed and numbered as (I) PH domain, (II) TH 
domain, (III) SH3 domain, (IV) SH2 domain, and (V) SH1 domain, as defined from 
Pfam database.  The skipped exon 9 which corresponds to 21 amino acid residues is 
bolded. 
 
                                              (Source: Bateman et al., 2002; Boeckmann et al., 2003) 
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Figure 4.7: The pedigree of the patient with XLA (III-2).  Boxes represent 
men and circles represent women.  Shapes with slashes represent deceased 
individuals. Shapes with a question mark represent individuals not 
accessible to the study.  Open shapes represent healthy individuals.  Solid 
shape represents affected patient.  Shapes with a dot represent carriers.   
 
 
 
 
  
 ?  ? 
I-1 I-2 
II-1 II-2 
II-4 II-5 
II-3 
III-1 III-2 
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5.0 DISCUSSION 
 
Bruton’s agammaglobulinemia was firstly described by Bruton in 1952 (Bruton,  
1952).  Bruton’s agammaglobulinemia is also known as X-linked agammaglobulinemia 
(XLA).  XLA is a classical type of B cell defects.  Majority patients with XLA tend to 
manifest symptoms at the age of 12 months, ranging from six to fourteen months, as the 
maternally acquired immunoglobulins diminish
 
(Lobo et al., 2003).  In this study, the 
patient had a history of recurrent pyogenic infections since he was one year old.   
  In view of low serum immunoglobulin levels and recurrent infections, three-
weekly IVIG replacement therapy was started in the patient.  The main source of 
immunoglobulin replacement therapy is human IgG obtained from pools of plasma of 
healthy blood donors (Maarschalk-Ellerbroek et al., 2011).  Most products contain no 
IgM and small amount of IgA.  IgM in an intravenous antibody replacement therapy, 
particularly, may form large complexes resulting in adverse reactions.  The purified 
products, therefore, contains more than 95% IgG.  The IgG repertoires are thought to 
reflect the immunity produced by previous exposure of various pathogens in the donors’ 
blood (Maarschalk-Ellerbroek et al., 2011).  Therefore, after immunoglobulin 
replacement therapy initiation, the patient’s serum IgG level was boosted up until 
achieving normal values, but not for serum IgM and IgA levels.   
The patient’s pre-IV IgG level was measured immediately prior to IVIg infusion 
whereas post-IV IgG level was measured after 24 hour or 48 hour of IVIg infusion as 
described in section 4.1.  Based on the patient’s serum immunoglobulin measurement 
history as described in section 4.1, the patient’s post-IV IgG level was higher than those 
prior to the next infusion.  As shown in Table 4.1 (section 4.1), after receiving 
intravenously administrated IgG, the infused IgG enters the bloodstream directly, hence, 
when measured, the serum IgG level increases drastically.  This serum IgG level 
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measured is denoted by post-IVIg IgG level in this study (Table 4.1).  Then, the IgG 
redistributes rapidly into tissue compartments, and then is catabolized slowly, therefore 
the serum IgG level is lower at the measuring time (Bonilla, 2008).  At this time, the 
serum IgG level measured is denoted by pre-IVIg IgG level (Table 4.1).  When the 
serum IgG level is lower than lower limit of protective value, the patient are susceptible 
to infections, therefore, another dose of IgG infusion will be needed.  The appropriate 
dose of immunoglobulin replacement therapy for antibody deficient patient is 
determined by the IgG trough level, the median half-life of IgG product and the intrinsic 
metabolism of the patient (Bonilla, 2008).  Waldmann, Strober and Blaese (1970), as 
quoted by Bonilla (2008) reported that the mean physiological catabolism half-life of 
IgG is about 23 days in healthy adults.  Therefore, three weekly of immunoglobulin 
replacement therapy is sufficient to replenish the IgG and protect the patient from 
infections.  Since receiving IVIg therapy, the patient remained well and suffered no 
further recurrent infections. 
BTK protein is a cytoplasmic tyrosine kinase that plays crucial role in B cell 
proliferation and differentiation.  Other than B cells, BTK is also expressed in 
monocytes (Futatani et al., 1998) and platelets (Futatani et al., 2001), but it is down-
regulated in T cells, natural killer cells and neutrophils (Futatani et al., 1998).  In this 
study, the patient had no circulating B cells.  To study the BTK protein expression in 
this patient, monocyte BTK protein expression was evaluated using flow cytometric 
analysis.  Flow cytometric analysis is a rapid and sensitive method to analyze monocyte 
BTK protein expression and has been widely used to diagnose XLA patients and to 
identify female carriers (Futatani et al., 1998; Kanegane et al., 2001; López-Granados et 
al., 2005).     
Intracellular staining of monocyte BTK expression with anti-BTK monoclonal 
antibody 48-2H by flow cytometry was firstly introduced by Futatani et al. (1998) and 
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successfully demonstrated deficient BTK protein expression in XLA patients.  However, 
the monoclonal antibody clone used in the study was from a different clone, 53/BTK.  
This clone was designed to target N-terminal of BTK protein, as stated by the 
manufacturer.  In this study, the genetic results showed that the patient had an invariant 
splice site mutation which caused a skipping of exon 9.  Zhu et al. (1994) reported an 
invariant splice site mutation at the same locus, but the base substitution was G>A, 
instead of G>C as identified in this study.  Zhu et al. (1994) also reported that the 
IVS9+1G>A mutation caused exon 9 skipping which resulted in an in-frame deletion of 
21 amino acids and a truncated BTK protein.  Hence, it is postulated that the point 
mutation seen in the studied patient would result in a truncated BTK protein with 21 
amino acids deletion as well.  Nine of these amino acids are located in the SH3 domain 
of the BTK protein (Figure 4.6).  The truncated mRNA expression was identified in the 
patient (Figure 4.2).  However, the truncated protein expression was unable to be 
identified (Figure 4.1).  The antibody used in the experiment was unable to bind to the 
truncated protein even if N-terminal was assumed to be remained intact to the protein in 
the patient.  The inability of the antibody to bind to truncated protein was reflected by 
the flow cytometric result, in which the studied patient’s monocytes were not stained 
with the antibody in spite of the truncated BTK protein was expressed as reported by 
Zhu et al. (1994).  The 6% monocytes BTK expression shown by flow cytometry in this 
study might be a non-specific interaction between the monoclonal antibodies and the 
targeted antigens. 
Monocyte BTK expression was defined based on isotype control using flow 
cytometry.  A carrier usually displays a bimodal BTK expression pattern of positive 
population and negative population in her monocytes (Futatani et al., 1998; Kanegane et 
al., 2001), but the ratio of these two populations varies among the female carriers 
(Futatani et al., 2001).  Interestingly, both mother and sister from the studied family 
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showed variant BTK expression patterns, instead of a classic bimodal BTK expression 
(Figure 4.1).  X-chromosome inactivation could be a possible explanation for the lack of 
classic bimodal distribution of monocytes’ BTK expression in both female carriers in 
this study.  Carrier status detection may be difficult if there is a significant skewing of X 
chromosome inactivation resulting in the majority of cells being either affected or 
unaffected.  In the case of significant skewing towards normality, carrier detection by 
sequencing would be essential. 
In order to clarify the carrier status, sequencing of BTK gene of cDNA and 
genomic DNA of the patient’s mother and sister was performed.  Both sequencing 
results showed that the patient's mother and sister had both normal and mutated alleles.  
The amplified genomic DNA from the mother and sister showed both G and C 
nucleotide at the same point, the first nucleotide at the 5’ end of intron 9 (Figure 4.4), 
reflecting that they are heterozygous at this locus.  The normal allele with G nucleotide 
would have normal intron splicing and produced a normal sequence, whereas the 
mutated allele with C nucleotide would lead to a splicing error and resulted in a 
skipping of exon 9.  In normal phenomenon, one of the X-chromosomes in females will 
be inactivated randomly, regardless of the parental origin, in order to achieve dosage 
compensation (Migeon, 2007).  In which, some of their cells express the paternal allele 
which was normal and some express the maternal allele which were mutated allele in 
this case study.  In this study, X-chromosome which carries the G allele, in the mother 
and the sister, is inherited from their father, whereas, the mutant allele, C allele, is 
inherited from their mother.  This mutant allele is the disease-causing allele, which is 
inherited from the mother.  Random inactivation happened in both mother and sister, 
whereby the X-chromosome which carried mutant allele was inactivated in some of 
their cells.  And, the other cells expressed X-chromosome which carried normal allele.  
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This cellular mosaicism resulted from X-chromosome inactivation protects them from 
suffering from disease.  Therefore, they are carriers and would appear healthy.   
In this study, the mutation IVS9+1G>C, as seen in the patient, resulted in a 
skipping of exon 9 (Figure 4.3), which lead to a missing of 21 amino acids.  Of all these 
21 amino acid residues, 260
th
 residue to 268
th
 residue, were located in the SH3 domain
 
of BTK protein (Figure 4.6).   Zhu et al. (1994) predicted that these amino acid residues 
were crucial for the formation of the putative SH3 ligand-binding pocket.  SH3 domain 
is involved in protein-protein interaction (Gaspar & Kinnon, 2001).  Therefore, 
disruption of this domain would affect the binding ability of BTK to its target.  Even if 
the functional domain remains intact, the alteration in the BTK binding capability to its 
target leads to the disease in the patient. 
In the aspect of immunological findings, the patient had no circulating B cell 
(Table 4.2), interestingly, he had a very low but detectable level of serum IgA, IgM and 
IgG before started on IVIg replacement therapy (Table 4.1).  This interesting finding 
was consistent with few studies in the literature, in which patients with XLA had 
virtually absence of circulating B cell in the peripheral blood, but they had very low 
serum IgA, IgM and IgG level remained in the blood at diagnosis and before receiving 
therapy (Lobo et al., 2003; Wang et al., 2009; Zhang et al., 2010).  Nonoyama et al. 
(1998) reported that in XLA patients there was a population of B cells that were able to 
proliferate, undergo isotype-switching and differentiate into specific antibody producing 
cells.  They termed these B cells as leaky B cells.  However, the origin of these leaky B 
cells is still to be determined.  These observations raised a few questions: What would 
be the origin of these leaky B cells? Can a splice site mutated gene produce wild-type 
transcript?  Interestingly, Noordzij et al. (2002) reported that patients with splice site 
mutation were able to produce low levels of wildtype BTK transcripts that were enough 
for a small amount of B cells development in these patients.  Similar observation was 
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found in the studied patient who had an IVS9+1G>C splice site mutation (Figure 4.4), 
and as such it is postulated that the same phenomenon may occur leading to the 
development of few leaky B cells that were mature enough to produce serum 
immunoglobulin.  Although the mechanism that leads to the production of wild type 
transcript from splice site mutation remain to be unveiled, Noordzij et al. (2002) 
produced evidence of wild type BTK transcript existence from splice site mutated BTK 
gene.  However, the origin of the leaky B cell is still unknown. 
Sequencing result of the genomic DNA revealed that the patient had a base 
change from nucleotide G to C, in the splice donor site, the first nucleotide at the 5’ end 
of intron 9 in the BTK gene (Figure 4.4).  The dinucleotide, GT, at the 5’ end of the 
intron and dinucleotide, AG, at the 3’ end of the intron are invariant splice sites and 
critical for a proper splicing of exon and intron.  Mutations in any nucleotide in these 
splice sites may lead to splicing errors, such as exon skipping, intron inclusion or 
activation of a proximal or distal cryptic splice site (Noordzij et al., 2002).  Point 
mutations affecting nucleotide ‘G’ of invariant splice donor site of intron 9, 
IVS9+1G>A, which resulted in exon 9 skipping and severe phenotype, have been 
described previously (Futatani et al., 2001; Zhu et al., 1994).
 
 Compared to these 
reported mutations, the patient in this study had a different base substitution in the first 
nucleotide of intron 9, and the mutation was IVS9+1G>C (Figure 4.4), which also 
resulted in a skipping of exon 9 (Figures 4.2 and 4.3).  Apart from the mutation 
described here, a base change or deletion of nucleotides 3’ downstream of the invariant 
donor splice site of intron 9, c.839+4A>G or c.839+(4_7)delAGTA, has also been 
described elsewhere, resulting in either a frame-shift mutation (E280fsX281) or a 
skipping of exon 9 (Lee et al., 2011; Tóth et al., 2009; Velickovic, Prasad, Weston, & 
Benson, 2004).  Other reports described the mutation c.838delGAGT involving exon 9 
and intron 9 resulted in either a frame-shift mutation (E280fs) (Danielian et al., 2003) or 
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skipping of exon 9 (Mesci et al., 2006).  Based on the study and reports as mentioned 
above, invariant splice donor site of intron 9 which is IVS9+1G could be a hotspot for 
BTK gene mutation. 
The common clinical features seen in the XLA patients with invariant splice 
donor site of intron 9 were recurrent pyogenic infections since young age, recurrent 
otitis media, bronchiectasis, low level of serum immunoglobulin and low B cells.  But, 
they might have other clinical features that may be related to this type of mutation.  The 
patient with mutation IVS9+1G>A, as described by Zhu et al. (1994), had chronic 
sinusitis and severe arthritis involving multiple joints; whereas the patient in this study 
had bronchopneumonia, asthma, failure to thrive and lower serum IgG level.  Allergy 
and asthma are very common in children, accounting for 155 million individuals 
worldwide (Cookson & Moffatt, 2000), however, asthma is rarely reported in XLA 
patients.  A study demonstrated that helper T cells of six XLA patients predominantly 
produced type-1 cytokine such as IFN-ɣ upon mitogen or antigen stimulation, instead of 
type-2 cytokine (Amedei et al., 2001).  Th1-type cytokine such as interferon gamma 
facilitates the production of opsonizing and complement-fixing antibodies by B cells, 
promotes cell-mediated immunity, macrophage activation and phagocytosis (Amedei et 
al., 2001; Ghadimi, de Vrese, Heller, & Schrezenmeir, 2010; Romagnani, 2008), while 
Th2-type cytokines contribute to asthma and allergy.  Amedei et al. (2001) described 
that XLA patients’ helper T cells tend to have bias towards Th1 response than Th2 
response hence it might protect them from allergy and asthma.  In the aspect of genetics, 
it has been reported that polymorphism or mutations in particular genes located at 
chromosomes 5, 6, 10, 11, 14 and 16 were associated with asthma phenotype (Hall, 
1998).  A more recent review paper suggested that the most consistent loci responsible 
for asthma and allergic disease are located on chromosomes 5, 6, 12 and 13 (Cookson & 
Moffatt, 2000) and none of the candidate genes is located in X-chromosome.    Based on 
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this information, it would be difficult to correlate asthma and XLA that was observed in 
this case study.  However, there was a report by Shabestari and Rezaei (2008) 
describing an XLA patient with asthma and allergic rhinitis.  They postulated that the T 
cell responses of that patient might be preferentially skewed to the Th2 pattern.  Th-2 
type cytokines such as IL-4, IL-5, IL-6, IL-9 and IL-13 are involved in recruitment and 
survival of eosinophils, growth and degranulation of mast cells and basophils, induction 
of B cell isotype class-switching to IgE production, and inhibition of several functions 
of macrophages (Berger, 2000; Lloyd & Hessel, 2010; Robinson, 2010; Romagnani, 
2008).  Type-2 cytokine, in other words, could contribute to asthma and allergy.  
However, the mechanism still needs to be elucidated.  It may be suggestive to include 
the investigation of the antigen-induced cytokine profile of T helper cells in Malaysian 
XLA patients in the future study. 
Zhu et al. (1994) demonstrated that a patient with a point mutation, IVS9+1G>A, 
had unaffected kinase activity even though the mutation truncated the BTK protein.  
The patient described in this thesis had also a point mutation, IVS9+1G>C, at the 
similar locus.  Therefore, it is interesting to assess the kinase activity. 
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6.0 SUMMARY  
 
In summary, the patient had a novel base substitution in the first nucleotide of 
intron 9, and the mutation was IVS9+1G>C.  Flow cytometric assay revealed that the 
patient lacked BTK protein expression in his monocytes, speculating that the absence of 
BTK expression in the B cells as well.  Absence of B cell BTK expression resulted in 
very low circulating B cells and antibodies, which rendered the patient susceptible to 
recurrent pyogenic infections, otitis media, bronchopneumonia, asthma, and failure to 
thrive.  Flow cytometric assay revealed that both mother and sister had BTK expression 
in nearly half of their monocytes.  Genetic study revealed that both mother and sister 
have heterozygous alleles at the similar mutational point as in the patient, confirming 
that both were carriers.  Based on the results obtained from the experiments, objective 1, 
2 and 3 that were set out for this study were achieved.  This study also determined all 
the requirements for the setting of a reliable small sample volume from the patient’s 
whole blood to diagnose XLA for clinical usage in the IMR.  Overall, this study 
supports the necessity of the combination of flow cytometry and genetic study in the 
diagnosis of XLA and the information would be useful for subsequent genetic 
counselling, carrier detection and prenatal diagnosis.   
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